Free Trial
NYSE:HAE

Haemonetics (HAE) Stock Price, News & Analysis

Haemonetics logo
$52.80 -0.68 (-1.26%)
As of 11:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Haemonetics Stock (NYSE:HAE)

Key Stats

Today's Range
$52.42
$53.46
50-Day Range
$52.14
$78.35
52-Week Range
$50.68
$94.99
Volume
152,854 shs
Average Volume
807,886 shs
Market Capitalization
$2.54 billion
P/E Ratio
16.15
Dividend Yield
N/A
Price Target
$82.50
Consensus Rating
Moderate Buy

Company Overview

Haemonetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

HAE MarketRank™: 

Haemonetics scored higher than 99% of companies evaluated by MarketBeat, and ranked 32nd out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Haemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Haemonetics has a consensus price target of $82.50, representing about 56.2% upside from its current price of $52.80.

  • Amount of Analyst Coverage

    Haemonetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Haemonetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Haemonetics are expected to grow by 10.77% in the coming year, from $4.55 to $5.04 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Haemonetics is 16.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.96.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Haemonetics is 16.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.73.

  • Price to Earnings Growth Ratio

    Haemonetics has a PEG Ratio of 0.99. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Haemonetics has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Haemonetics' valuation and earnings.
  • Percentage of Shares Shorted

    7.72% of the float of Haemonetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Haemonetics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Haemonetics has recently decreased by 16.02%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Haemonetics does not currently pay a dividend.

  • Dividend Growth

    Haemonetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.72% of the float of Haemonetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Haemonetics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Haemonetics has recently decreased by 16.02%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Haemonetics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Haemonetics this week, compared to 7 articles on an average week.
  • Search Interest

    1 people have searched for HAE on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Haemonetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.84% of the stock of Haemonetics is held by insiders.

  • Percentage Held by Institutions

    99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Haemonetics' insider trading history.
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HAE Stock News Headlines

Q1 EPS Estimates for Haemonetics Boosted by Zacks Research
Haemonetics Corporation (NYSE:HAE) Sees Large Growth in Short Interest
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Zacks Research Estimates Haemonetics' Q1 Earnings (NYSE:HAE)
See More Headlines

HAE Stock Analysis - Frequently Asked Questions

Haemonetics' stock was trading at $78.08 at the start of the year. Since then, HAE shares have decreased by 32.4% and is now trading at $52.8040.

Haemonetics Corporation (NYSE:HAE) issued its earnings results on Thursday, August, 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The firm's revenue was down 4.4% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of Haemonetics include River Road Asset Management LLC (3.44%), Geode Capital Management LLC (2.59%), Boston Trust Walden Corp (2.27%) and Allspring Global Investments Holdings LLC (1.98%). Insiders that own company stock include Michelle L Basil, Anila Lingamneni, Josep Llorens, Stewart W Strong and Laurie A Miller.
View institutional ownership trends
.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/07/2025
Today
9/12/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Supplies
Current Symbol
NYSE:HAE
CIK
313143
Employees
3,023
Year Founded
1971

Price Target and Rating

High Price Target
$116.00
Low Price Target
$62.00
Potential Upside/Downside
+56.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.27
Trailing P/E Ratio
16.15
Forward P/E Ratio
11.61
P/E Growth
0.99
Net Income
$167.68 million
Net Margins
12.14%
Pretax Margin
15.64%
Return on Equity
26.64%
Return on Assets
9.32%

Debt

Debt-to-Equity Ratio
1.04
Current Ratio
1.72
Quick Ratio
1.04

Sales & Book Value

Annual Sales
$1.35 billion
Price / Sales
1.89
Cash Flow
$7.09 per share
Price / Cash Flow
7.45
Book Value
$16.34 per share
Price / Book
3.23

Miscellaneous

Outstanding Shares
48,177,000
Free Float
47,291,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
0.39

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:HAE) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners